ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
miR-130a-3p Exacerbates Sepsis-Induced Cardiac Dysfunction by Promoting Inflammation and Targeting PDK4.
Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundSepsis is frequently complicated by systemic inflammatory injury and cardiac dysfunction, which serve as risk factors of adverse clinical outcomes and increased mortality risk. To clarify the function of miR-130a-3p in sepsis diagnosis and its regulatory role in sepsis-induced inflammatory injury and cardiac dysfunction, based on clinical analysis and cellular assays.MethodsThe study recruited 126 patients with sepsis and an matched number of healthy controls. The potential of miR-130a-3p to differentiate between sepsis and healthy controls was evaluated by receiver operating characteristic (ROC) curve. Quantify miR-130a-3p and PDK4 levels using real-time quantitative polymerase chain reaction (RT-qPCR). Indicators of inflammation, cardiac dysfunction and oxidative stress in cells were assessed by corresponding biochemical assays and enzyme-linked immunosorbent assay (ELISA) kits. The functional properties of H9C2 cells were evaluated by cell counting kit-8 (CCK-8) assay and flow cytometry. Bioinformatics analysis and luciferase activity assays were employed to identify the downstream targets of miR-130a-3p.ResultsH9C2 cell viability was impaired, with the increased levels of interleukin-1beta (IL-1β), interleukin-6 (IL-6), cardiac troponin I (cTnI), creatine kinase MB (CK-MB), malondialdehyde (MDA), and decreased superoxide dismutase (SOD) activity. When miR-130a-3p expression was repressed, the levels of inflammation and cardiac dysfunction indicators were diminished, and the oxidative stress damage and cell viability was restored. PDK4 is a direct target of miR-130a-3p and is low-expressed in sepsis patients and LPS-induced H9C2 cells.ConclusionmiR-130a-3p modulates inflammatory response and cardiac dysfunction by mediating PDK4, representing a potential effective target for sepsis diagnosis and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.